The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort

• DOI: 10.1016/j.trci.2018.02.002
• Publication Date: 2018-03-08T14:54:57Z
• Authors: Pierre N. Tariot; Francisco Lopera; Jessica B. Langbaum; Ronald G. Thomas; Suzanne Hendrix; Lon S. Schneider; Silvia Rios‐Romenets; Margarita Giraldo; Natalia Acosta; Carlos Tobon; Claudia Ramos; Alejandro Espinosa; William Cho; Michael Ward; David Clayton; Michael Friesenhahn; Howard Mackey; Lee Honigberg; Sandra Sanabria B...; Kewei Chen; Trisha Walsh; Carolyn Langlois; Eric M. Reiman
• Keywords: PSEN1

Autosomal-dominant Alzheimer's disease (ADAD) represents a crucial population for identifying prevention strategies that might modify course cognitively unimpaired individuals at high imminent risk developing symptoms due to (AD), is, who have "preclinical" AD. Crenezumab is an antiamyloid monoclonal antibody binds monomeric and aggregated forms of amyloid β, with highest affinity oligomers; it in development early stages sporadic AD ADAD.